Chugai Signs License Agreement With Rani Therapeutics for Oral Biologics Development

Reuters

10/20

Chugai Signs License Agreement With Rani <a href="https://laohu8.com/S/LENZ">Therapeutics</a> for Oral Biologics Development

Chugai Pharmaceutical Co., Ltd. has announced a license agreement with Rani Therapeutics for the development and commercialization of an oral formulation leveraging RaniPill® technology. Under the terms of the agreement, Chugai will make an upfront payment of $10 million to Rani Therapeutics, with the potential for up to $75 million in technology transfer and development milestone payments, and up to $100 million in sales-based milestone payments, contingent on the commercial success of the molecule. Additional single digit royalties on sales are also included if commercialization is successful. Chugai has the option to extend its rights to five additional targets under similar terms, potentially bringing the total deal value to over $1 billion if fully exercised. This agreement is not expected to impact Chugai's consolidated financial forecast for the fiscal year ending December 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2576004464"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576004464\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576004464?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 07:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576004464","market":"nz","top_or_hot":-1,"title":"Chugai Signs License Agreement With Rani Therapeutics for Oral Biologics Development","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Chugai Signs License Agreement With Rani <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for Oral Biologics Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CHGCF\">Chugai Pharmaceutical Co., Ltd.</a> has announced a license agreement with Rani Therapeutics for the development and commercialization of an oral formulation leveraging RaniPill® technology. Under the terms of the agreement, Chugai will make an upfront payment of $10 million to Rani Therapeutics, with the potential for up to $75 million in technology transfer and development milestone payments, and up to $100 million in sales-based milestone payments, contingent on the commercial success of the molecule. Additional single digit royalties on sales are also included if commercialization is successful. Chugai has the option to extend its rights to five additional targets under similar terms, potentially bringing the total deal value to over $1 billion if fully exercised. This agreement is not expected to impact Chugai's consolidated financial forecast for the fiscal year ending December 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chugai Signs License Agreement With Rani Therapeutics for Oral Biologics Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChugai Signs License Agreement With Rani Therapeutics for Oral Biologics Development\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-20 07:33</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Chugai Signs License Agreement With Rani <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for Oral Biologics Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CHGCF\">Chugai Pharmaceutical Co., Ltd.</a> has announced a license agreement with Rani Therapeutics for the development and commercialization of an oral formulation leveraging RaniPill® technology. Under the terms of the agreement, Chugai will make an upfront payment of $10 million to Rani Therapeutics, with the potential for up to $75 million in technology transfer and development milestone payments, and up to $100 million in sales-based milestone payments, contingent on the commercial success of the molecule. Additional single digit royalties on sales are also included if commercialization is successful. Chugai has the option to extend its rights to five additional targets under similar terms, potentially bringing the total deal value to over $1 billion if fully exercised. This agreement is not expected to impact Chugai's consolidated financial forecast for the fiscal year ending December 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RANI","symbol_name":"Rani Therapeutics Holdings","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251019:nNDLbr50Ry:1","article_id":"2576004464","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576004464","pubTimestamp":1760916838,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Chugai Pharmaceutical Co., Ltd. has announced a license agreement with Rani Therapeutics for the development and commercialization of an oral formulation leveraging RaniPill technology. Under the terms of the agreement, Chugai will make an upfront payment of $10 million to Rani Therapeutics, with the potential for up to $75 million in technology transfer and development milestone payments, and up to $100 million in sales-based milestone payments, contingent on the commercial success of the molecule. Additional single digit royalties on sales are also included if commercialization is successful. Chugai has the option to extend its rights to five additional targets under similar terms, potentially bringing the total deal value to over $1 billion if fully exercised. This agreement is not expected to impact Chugai's consolidated financial forecast for the fiscal year ending December 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RANI":"Rani Therapeutics Holdings","BK4539":"次新股","BK4007":"制药"},"translate_title":"中外制药与Rani Therapeutics签署口服生物制剂开发许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RANI":0.9},"content_text":"Chugai Signs License Agreement With Rani Therapeutics for Oral Biologics Development\n    \n\nChugai Pharmaceutical Co., Ltd. has announced a license agreement with Rani Therapeutics for the development and commercialization of an oral formulation leveraging RaniPill® technology. Under the terms of the agreement, Chugai will make an upfront payment of $10 million to Rani Therapeutics, with the potential for up to $75 million in technology transfer and development milestone payments, and up to $100 million in sales-based milestone payments, contingent on the commercial success of the molecule. Additional single digit royalties on sales are also included if commercialization is successful. Chugai has the option to extend its rights to five additional targets under similar terms, potentially bringing the total deal value to over $1 billion if fully exercised. This agreement is not expected to impact Chugai's consolidated financial forecast for the fiscal year ending December 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}